HeartFlow: 3 Key Takeaways for Long-Term Investors
Heartflow, Inc. Common Stock Q3 2026 Earnings Call Summary
Wells Fargo Maintains Overweight on HeartFlow, Raises Price Target to $70
Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $69
Stifel Maintains Buy on HeartFlow, Raises Price Target to $70
Baird Maintains Outperform on HeartFlow, Raises Price Target to $68
HeartFlow (HTFL) Q3 2026 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q3 2026 Earnings Call Transcript
HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates
HeartFlow: Q3 Earnings Snapshot
Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
HeartFlow Q3 Adj. EPS $(0.03) Beats $(0.10) Estimate, Sales $72.857M Beat $65.264M Estimate
HeartFlow Raises FY2026 Sales Guidance from $246.000M-$250.000M to $262.000M-$264.000M vs $248.778M Est
HeartFlow (HTFL) Stock May Be Overvalued On Fresh Plaque Analysis Data
HeartFlow (HTFL) Shares Moved, What Is Behind The Attention?
AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry
Heartflow To Present DECIDE Registry Data Showing 34% Reduction In Major Cardiovascular Events With AI Plaque Analysis, At AHA Scientific Sessions 2026
TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
Reported October 22, 2026: 'Heartflow Says Elucid Stole Trade Secrets, Infringed Patents' - Bloomberg Law
Piper Sandler Reiterates Overweight on HeartFlow, Raises Price Target to $64
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.